17β-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line

  • Authors:
    • Zbynek Heger
    • Jaromir Gumulec
    • Natalia Cernei
    • Katerina Tmejova
    • Pavel Kopel
    • Jan Balvan
    • Michal Masarik
    • Ondrej Zitka
    • Miroslava Beklova
    • Vojtech Adam
    • Rene Kizek
  • View Affiliations

  • Published online on: November 26, 2014     https://doi.org/10.3892/or.2014.3627
  • Pages: 921-929
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study suggests and describes the application of a delivery system for antisense oligonucleotides against mRNA encoding estrogen receptor proteins α and β. The delivery system is composed of a cationic liposome envelope containing 17β-estradiol (E2) in its structure. Cationic liposomes protect cargo against the extracellular matrix, and E2 can increase its shuttling efficiency into cells. Using MCF-7 cells derived from estrogen receptor-positive ductal carcinoma, treatment with liposomes against ERα was found to decrease MCF-7 proliferation, and importantly the application of both the antisense against ERα and β exhibited an antiproliferative effect expressed as cell viability. Using qRT-PCR, it was shown that MT1A, NF-κB1 and K-ras genes, but not TFF1, were downregulated using E2-based liposomes (evaluated at P=0.05). Further indicators of oxidative stress were employed to assess the effect on treatment efficiency. Glutathione (GSH/GSSG redox ratio), metallothionein (MT) and malondialdehyde (MDA) confirmed a positive effect of antisense therapy resulting in their decreased levels in the MCF-7 cells. Based on these data, we suggest that E2-based liposomes offer sufficient transfer efficiency and moreover, due to the effect on NF-κB1, MT and GSH, tumor cells can be chemosensitized to increase treatment effectiveness.
View Figures
View References

Related Articles

Journal Cover

February-2015
Volume 33 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Heger Z, Gumulec J, Cernei N, Tmejova K, Kopel P, Balvan J, Masarik M, Zitka O, Beklova M, Adam V, Adam V, et al: 17β-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line. Oncol Rep 33: 921-929, 2015
APA
Heger, Z., Gumulec, J., Cernei, N., Tmejova, K., Kopel, P., Balvan, J. ... Kizek, R. (2015). 17β-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line. Oncology Reports, 33, 921-929. https://doi.org/10.3892/or.2014.3627
MLA
Heger, Z., Gumulec, J., Cernei, N., Tmejova, K., Kopel, P., Balvan, J., Masarik, M., Zitka, O., Beklova, M., Adam, V., Kizek, R."17β-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line". Oncology Reports 33.2 (2015): 921-929.
Chicago
Heger, Z., Gumulec, J., Cernei, N., Tmejova, K., Kopel, P., Balvan, J., Masarik, M., Zitka, O., Beklova, M., Adam, V., Kizek, R."17β-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line". Oncology Reports 33, no. 2 (2015): 921-929. https://doi.org/10.3892/or.2014.3627